Journal of Gynecologic Oncology最新文献

{"title":"Primary chemoradiation versus radical hysterectomy with lymphadenectomy for stage IIICr cervical cancer without parametrial involvement: gynecologic oncology research investigators collaboration study (GORILLA-1002).","authors":"Kyung Hee Han, Eunjung Yang, Namkyeong Kim, Joo-Hyuk Son, Tae Wook Kong, Seung-Hyuk Shim, Dong Hoon Suh, Suk-Joon Chang, Hee Seung Kim","doi":"10.3802/jgo.2026.37.e89","DOIUrl":"10.3802/jgo.2026.37.e89","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effectiveness and adverse events of primary chemoradiation versus radical hysterectomy with pelvic or para-aortic lymphadenectomy in patients with 2018 International Federation of Gynecology and Obstetrics stage IIICr cervical cancer without clinical parametrial involvement.</p><p><strong>Methods: </strong>This retrospective study included patients diagnosed with stage IIICr cervical cancer who had pelvic or para-aortic lymph nodes measuring at least 1 cm in short diameter on preoperative imaging between 2000 and 2020. Primary chemoradiation consisted of external beam radiation therapy and brachytherapy, while adjuvant chemoradiation following radical surgery was administered based on pathological results.</p><p><strong>Results: </strong>A total of 204 patients underwent primary chemoradiation (n=66) or radical hysterectomy with systematic lymphadenectomy (n=138). There were no significant differences in disease stage or histological type between the groups. In patients with tumors ≥4 cm, primary chemoradiation improved progression-free survival (PFS) compared to radical surgery (5-year survival: 91.1% vs. 61.7%; p<0.005). Favorable factors for PFS included stage IIIC1 disease, primary chemoradiation, and tumor size <4 cm. Stage IIIC1 was associated with better PFS and overall survival than stage IIIC2 (p=0.048 and p=0.020, respectively). Central recurrence was more common after primary chemoradiation, while pelvic sidewall or distant recurrence was more frequent after radical hysterectomy with lymphadenectomy (p=0.009). Anemia was more frequent in the primary chemoradiation group, while lymphedema was less common than in the radical surgery group.</p><p><strong>Conclusion: </strong>Primary chemoradiation may be more effective than radical hysterectomy with systematic lymphadenectomy in patients with stage IIICr cervical cancer without parametrial invasion.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e89"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct comparison of 5-aminolevulinic acid photodynamic diagnosis and white light inspection for detecting peritoneal dissemination in advanced ovarian cancer: a pilot study.","authors":"Akira Yabuno, Daisuke Shintani, Masakazu Sato, Sho Sato, Masanori Yasuda, Kosei Hasegawa","doi":"10.3802/jgo.2026.37.e85","DOIUrl":"10.3802/jgo.2026.37.e85","url":null,"abstract":"<p><strong>Objective: </strong>Protoporphyrin IX, a metabolite of 5-aminolevulinic acid (5-ALA), emits red fluorescence. Photodynamic diagnosis (PDD) using 5-ALA has been successfully applied in fluorescence-guided surgery for various malignancies. This pilot study directly compared the diagnostic performance of conventional white light (WL) inspection and 5-ALA-based PDD for detecting intraperitoneal dissemination in advanced ovarian cancer (OC).</p><p><strong>Methods: </strong>This prospective single-center study included patients with advanced OC undergoing staging laparoscopy. Each patient received oral 5-ALA (20 mg/kg) 4 hours preoperatively. Tumor and non-tumor locations were identified under WL and fluorescent light (FL). Biopsy specimens were collected from tumor locations visible under both WL and FL, only under WL, and only under FL and from non-tumor locations visible under both WL and FL. Pathological examination confirmed malignancy, and results were correlated with imaging findings.</p><p><strong>Results: </strong>Seven patients were enrolled between January and March 2019 and 71 biopsies were performed. The diagnoses included four cases of high-grade serous carcinoma, one clear cell carcinoma, one grade 3 endometrioid carcinoma, and one pseudomyxoma peritonei. The sensitivity, specificity, positive predictive value, and negative predictive value for detecting malignancy under WL were 87.8%, 59.0%, 82.7%, and 68.4%, respectively, compared with 96.0%, 90.5%, 96.0%, and 90.5% under FL. Additional metastatic lesions were identified in three patients subjected to 5-ALA imaging. No severe 5-ALA-related adverse events were observed.</p><p><strong>Conclusion: </strong>5-ALA-based PDD demonstrated higher diagnostic accuracy than WL for detecting intraperitoneal dissemination of advanced OC. Its ability to enhance tumor detection may improve surgical precision and outcomes.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e85"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer.","authors":"Asami Matsunaga, Miho Ogawa, Akiko Kunita, Yuji Ikeda, Kosuke Kashiwabara, Yuki Okuma, Osamu Kobayashi, Nobuki Hayashi, Takahiro Nakajima, Qian Xi, Mirei Ka, Saki Kamata, Keisuke Saitou, Yoko Nakanishi, Shinobu Masuda, Kousuke Watanabe, Aya Shinozaki-Ushiku, Tetsuo Ushiku, Hidenori Kage, Kei Kawana, Katsutoshi Oda","doi":"10.3802/jgo.2026.37.e99","DOIUrl":"10.3802/jgo.2026.37.e99","url":null,"abstract":"<p><strong>Objective: </strong>Circulating tumor human papillomavirus (HPV) DNA (ctHPV DNA) has shown clinical utility in advanced cervical cancer; however, its role in surgically resected disease remains unclear. We evaluated the detectability and clinicopathological associations of ctHPV DNA in preoperative plasma from patients with surgically resected cervical cancer using digital polymerase chain reaction (dPCR).</p><p><strong>Methods: </strong>We analyzed 49 surgically resected cervical cancer patients. HPV genotyping of formalin-fixed paraffin-embedded tumor tissues was performed using both PGMY09/11 consensus PCR and novel genotype-specific dPCR assays targeting 6 high-risk HPV types (16, 18, 31, 39, 45, and 52). Plasma cell-free DNA was analyzed using dPCR for HPV genotypes. Associations between ctHPV DNA copy number and clinicopathological features were evaluated.</p><p><strong>Results: </strong>HPV genotypes were identified in 42 of 49 tumor tissues (85.7%), with dPCR showing superior sensitivity (95.8%) compared to the PGMY method (77.6%). ctHPV DNA was detected in 12 of 42 evaluable plasma samples (28.6%), and plasma genotypes were concordant with those of the corresponding tumor tissues. ctHPV DNA copy numbers were significantly higher in cases with lymphovascular invasion (p=0.034) and lymph node metastasis (p=0.010), but were not correlated with tumor size, stage, or histologic type. ctHPV DNA was more consistently detectable than <i>PIK3CA</i> hotspot mutations in plasma, supporting its robustness as a biomarker in liquid biopsy settings.</p><p><strong>Conclusion: </strong>This study highlights ctHPV DNA as a promising noninvasive biomarker in surgically resected cervical cancer. Its association with lymphovascular invasion and lymph node metastasis supports its potential role in preoperative risk stratification and personalized surgical planning.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e99"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent patterns and trends in global ovarian cancer incidence and mortality in adolescents and young adults.","authors":"Yongming Du, Yichao Hu, Huiqing Ding, Yutao Guan","doi":"10.3802/jgo.2026.37.e106","DOIUrl":"10.3802/jgo.2026.37.e106","url":null,"abstract":"<p><strong>Objective: </strong>Ovarian cancer in adolescents and young adults (AYAs, aged 15-39 years) presents distinct clinical and epidemiological characteristics, yet comprehensive global epidemiological data remain limited.</p><p><strong>Methods: </strong>We conducted a comprehensive analysis using 3 International Agency for Research on Cancer databases: GLOBOCAN 2022, Cancer Incidence in Five Continents Plus, and World Health Organization (WHO) mortality database. Age-standardized incidence rates (ASIRs) and mortality rates (ASMRs) per 100,000 women-years were calculated using the WHO World Standard Population. Countries were stratified by Human Development Index (HDI). Temporal trends were analyzed using Joinpoint regression to calculate annual percent change and average annual percent change (AAPC).</p><p><strong>Results: </strong>In 2022, global ASIRs for AYAs (15-39 years) ovarian cancer demonstrated relative uniformity across regions, with highest rates in Melanesia. ASMRs exhibited an inverse HDI gradient, with low-HDI regions experiencing highest mortality burdens (0.75 per 100,000 women-years) despite lower incidence (2.02 per 100,000 women-years). Analysis of the most recent 5-year period revealed divergent trends, characterized by a significant rise in incidence in Thailand (AAPC=6.62%; 95% confidence interval [CI]=1.84%, 11.52%) across 44 regions and marked mortality elevations in the Syrian Arab Republic (AAPC=15.89%; 95% CI=10.29%, 21.64%) and Venezuela (AAPC=11.08%; 95% CI=8.06%, 14.01%) in 59 regions.</p><p><strong>Conclusion: </strong>Despite relatively uniform global incidence, mortality from ovarian cancer in AYAs shows pronounced international disparities, with the greatest burden concentrated in low-HDI regions. Evidence from divergent incidence-mortality trajectories indicating that healthcare improvements enhance survival highlights the critical need for targeted interventions to address global disparities in AYA ovarian cancer outcomes.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e106"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high-grade epithelial ovarian cancer'.","authors":"Siyuan Zhu","doi":"10.3802/jgo.2026.37.e131","DOIUrl":"10.3802/jgo.2026.37.e131","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e131"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Who should participate in laparoscopic surgery trials for early cervical cancer? Surgeon authority and selection bias in randomized studies of open versus minimally invasive surgery for early-stage cervical cancer.","authors":"Kenro Chikazawa, Rika Ozawa, Tomoyuki Kuwata","doi":"10.3802/jgo.2027.38.e18","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e18","url":null,"abstract":"","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and risk factors by histologic type of malignant ovarian germ cell tumors in Japan: a JSOG gynecologic tumor registry-based study.","authors":"Hirotsugu Sakaki, Tsuyoshi Ohta, Wataru Yamagami, Fumiaki Takahashi, Hideki Tokunaga, Eiko Yamamoto, Yoshihito Yokoyama, Kiyoshi Yoshino, Kei Kawana, Satoru Nagase","doi":"10.3802/jgo.2027.38.e16","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e16","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated prognosis and risk factors for overall survival (OS) in malignant ovarian germ cell tumors (MOGCTs) using data from the Japan Society of Obstetrics and Gynecology tumor registry.</p><p><strong>Methods: </strong>Data from 1,538 MOGCT patients (2004-2019) were retrospectively analyzed. Factors such as age, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic subtype, lymph node status, and surgical outcomes were examined. Kaplan-Meier curves and Cox proportional hazards regression analyses were used to assess OS.</p><p><strong>Results: </strong>The histologic distribution was immature teratoma (56.6%), yolk sac tumor (28.7%), dysgerminoma (10.0%), and mixed germ cell tumor (9.6%). The 5-year OS rate was 94.8% overall, with the highest OS in dysgerminoma (97.4%) and the lowest in mixed germ cell tumors (87.2%). Advanced FIGO stage and incomplete surgical resection were significant predictors of poorer OS across subtypes. Age ≥50 years was independently associated with poorer OS in yolk sac tumor, immature teratoma grade 3, and mixed germ cell tumor. Although favorable survival outcomes were observed in patients with advanced-stage yolk sac tumors, the present registry-based study was not designed to evaluate the impact of specific chemotherapy regimens.</p><p><strong>Conclusion: </strong>MOGCTs demonstrate favorable survival outcomes in Japan. However, advanced FIGO stage, incomplete surgical resection, and older age were significant risk factors for poorer OS in specific subtypes. The observed survival patterns may reflect contemporary multidisciplinary management, but definitive conclusions regarding specific chemotherapy regimens cannot be drawn from this registry-based analysis.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey on the current status of novel cancer drug therapies for gynecological cancers in Japan: a nationwide survey by the Japan Society of Obstetrics and Gynecology (JSOG).","authors":"Yusuke Kobayashi, Hidemichi Watari, Katsutoshi Oda, Hidetaka Nomura, Kosei Hasegawa, Noriomi Matsumura, Hirotaka Nishi, Yoh Watanabe, Hiroaki Komatsu, Kenta Masuda, Daisuke Aoki, Toyomi Satoh, Kei Kawana, Kiyoko Kato","doi":"10.3802/jgo.2027.38.e20","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e20","url":null,"abstract":"<p><strong>Objective: </strong>To characterize real-world implementation of novel therapies in gynecological oncology in Japan and identify actionable gaps through a nationwide survey.</p><p><strong>Methods: </strong>A cross-sectional questionnaire was distributed to Japan Society of Obstetrics and Gynecology-affiliated institutions. The items covered institution characteristics; use of poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors (ICIs), kinase inhibitors, and antibody-based agents; local adverse event (AE) manuals; availability of expert panels and immune-related adverse event (irAE) teams; and perceptions of educational sufficiency.</p><p><strong>Results: </strong>Valid responses were obtained from 245 institutions, spanning universities, cancer centers, and general hospitals. Most institutions reported the routine use of PARP inhibitors, ICIs, kinase inhibitors, and antibody drugs. However, only 40.4% of institutions had an in-hospital irAE management team, 57.1% had an AE/irAE manual, and 31.0% and 12.2% considered prior educational opportunities sufficient for physicians and nurses/other medical staff, respectively. High-volume institutions and academic centers were significantly more likely to have medical oncology support, expert-panel access, irAE teams, manuals, and higher self-rated evidence-based management capacity. The majority favored e-learning and society-led case conferences, and 76.3% supported the development of drug therapy subspecialties in gynecologic oncology.</p><p><strong>Conclusion: </strong>Innovative drug modalities are widely implemented across Japanese gynecological oncology services. However, critical gaps persist in multidisciplinary irAE management, standardized manuals, and practical education. Coordinated society-led programs to expand irAE teams, streamline companion diagnostics, disseminate ready-to-use algorithms, and provide credential-targeted training may enhance safety, equity, and evidence-concordant care nationwide.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic features and outcomes of patients with microsatellite instability-high endometrial cancer treated with pembrolizumab in Japan: the KCOG-G1902S/1903S study.","authors":"Yoko Kashima, Kosuke Murakami, Tomoyuki Otani, Kaori Yoriki, Michiko Kaneda, Satoe Fujiwara, Takahiro Katsuda, Hiroaki Nagano, You Hayasaki, Kentaro Kai, Atsushi Arakawa, Ayako Mochizuki, Yasuyuki Hirashima, Naoyuki Iwahashi, Takashi Motohashi, Emi Yoshioka, Kimihiko Ito, Hidekatsu Nakai, Noriomi Matsumura","doi":"10.3802/jgo.2027.38.e19","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e19","url":null,"abstract":"<p><strong>Objective: </strong>To characterize clinicopathologic features of microsatellite instability-high (MSI-high) gynecologic malignancies in Japan and evaluate outcomes of pembrolizumab in MSI-high endometrial cancer, including an exploratory assessment of <i>MLH1</i> promoter methylation and obesity.</p><p><strong>Methods: </strong>Gynecologic malignancies undergoing routine MSI testing at 11 institutions were registered (KCOG-G1902S). Clinicopathologic data of MSI-high cases were collected from medical records. Patients with MSI-high endometrial cancer treated with pembrolizumab were prospectively followed (KCOG-G1903S). <i>MLH1</i> promoter methylation was assessed in tumors with MLH1 loss, and exploratory analyses evaluated outcomes according to <i>MLH1</i> methylation status and body mass index (BMI).</p><p><strong>Results: </strong>Among 529 tumors tested, 56 (10.6%) were MSI-high, most arising in the endometrium (52/251; 20.7%). MSI-high tumors from other organs were predominantly endometrioid. All MSI-high tumors showed mismatch repair protein loss on immunohistochemistry; 41/56 (73.2%) demonstrated PMS2 and/or MLH1 loss. Pembrolizumab was administered to 25 patients with MSI-high endometrial cancer. The objective response rate was 48% (12/25), with median progression-free survival (PFS) of 21.2 months and overall survival of 58.1 months. <i>MLH1</i> promoter methylation was detected in 17/18 tumors with MLH1 loss. In exploratory analyses, patients with at least one favorable factor (absence of <i>MLH1</i> methylation and/or BMI ≥30 kg/m²) had higher response rates (77.8% vs. 31.3%, p=0.041) and longer PFS (p=0.039).</p><p><strong>Conclusion: </strong>MSI-high gynecologic malignancies arise predominantly in the endometrium. Pembrolizumab demonstrated durable activity in MSI-high endometrial cancer. <i>MLH1</i> promoter methylation status, and possibly obesity, may provide clinically relevant insights into the heterogeneity of pembrolizumab response. These findings are exploratory and require validation in larger cohorts.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term trends and future projections of cervical cancer burden in China, 1990-2023: a Global Burden of Disease 2023 analysis.","authors":"Chao Ma, Ping Yin, Nan Hong","doi":"10.3802/jgo.2027.38.e15","DOIUrl":"https://doi.org/10.3802/jgo.2027.38.e15","url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer remains a major public health challenge among women in China. This study aimed to comprehensively assess long-term trends and future projections of cervical cancer burden in China.</p><p><strong>Methods: </strong>Data on cervical cancer in China from 1990 to 2023 were extracted from Global Burden of Disease Study2023. Prevalence, incidence, deaths, years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and age-standardized rates (ASRs) were analyzed. Temporal trends were evaluated using estimated annual percentage change (EAPC) and Joinpoint regression. Das Gupta decomposition quantified the contributions of population growth, aging, and epidemiological change. Nordpred was used to project deaths and DALYs from 2024 to 2045.</p><p><strong>Results: </strong>From 1990 to 2023, prevalent cervical cancer cases increased from 445,795 (95% uncertainty interval [UI]=301,749-642,609) to 752,306 (95% UI=481,273 to 1,011,544). YLDs increased by 62%, whereas YLLs decreased by 4%. Overall DALYs decreased slightly from 1,457,115 (95% UI=1,070,025 to 2,064,940) to 1,430,054 (95% UI=896,628 to 1,874,757), while deaths increased by 16%. Age-standardized DALYs rate (ASDR) declined from 294.14 to 132.72 per 100,000 population, with an EAPC of -2.43 (95% confidence interval=-2.54 to -2.33). Decomposition showed that population aging and growth offset favorable epidemiological changes, and projections suggested continued declines in ASDR with relatively stable deaths through 2045.</p><p><strong>Conclusion: </strong>Despite sustained declines in ASRs, the absolute burden of cervical cancer in China remains considerable due to demographic shifts. These findings underscore the urgent need to strengthen human papillomavirus vaccination coverage and expand equitable cervical cancer screening programs.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}